Opportunity Information: Apply for PA 10 032
Apply for PA 10 032
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Epigenetic Approaches in Cancer Epidemiology (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control.
- This funding opportunity was created on Nov 24, 2009 and posted on Nov 24, 2009.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Public and State controlled institutions of higher education State governments For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI) grant opportunity titled "Epigenetic Approaches in Cancer Epidemiology (R21)" (Funding Opportunity Number PA-10-032) was designed to support exploratory, population-based research that connects epigenetic patterns to cancer risk across different groups of people. The central idea is to move beyond purely genetic explanations of cancer by examining molecular features that can change over time and may be influenced by environment, behavior, aging, and other exposures. Specifically, the FOA encourages applications that measure and analyze epigenetic profiles such as DNA methylation, histone modifications, and microRNA (miRNA) expression, then evaluate how those profiles are associated with the likelihood of developing cancer. The bigger picture goal is to improve understanding of cancer etiology by identifying epigenetic markers that may help explain why cancer arises and why risk differs across populations.
This opportunity uses the NIH Exploratory/Developmental Research Grant mechanism (R21), which generally fits early-stage, proof-of-concept, or method-development work where investigators are testing innovative ideas or generating preliminary data that could later support a larger R01-scale project. In line with that intent, the FOA is positioned as a parallel companion to an R01 opportunity of the same scientific scope (PA-10-031). In practice, that pairing signals that NCI was seeking both smaller, higher-risk exploratory studies through the R21 and more fully powered projects through the R01, all aimed at clarifying the role of epigenetic alterations in cancer development at the population level.
From a funding standpoint, the FOA listed an award ceiling of $200,000 (as provided in the source data) and noted that awards would depend on the availability of funds and the number of high-quality applications received, rather than guaranteeing a fixed number of awards. There was no cost sharing or matching requirement. The funding activity category is listed under Education/Health, with CFDA number 93.399 (Cancer Control), reflecting its placement within NCI's broader cancer control and population sciences priorities.
Eligibility was broad and included many organization types, such as public and private institutions of higher education, state governments, for-profit organizations (including those other than small businesses), small businesses, and nonprofit organizations with or without 501(c)(3) status (as long as they met the criteria described in the FOA). The eligibility language also explicitly included additional categories such as eligible federal agencies, non-U.S. (foreign) entities, and regional organizations, which indicates NCI was open to a wide range of institutional applicants and collaborative structures, including international work where appropriate for population comparisons or unique cohorts.
Administratively, the opportunity was posted and created on November 24, 2009, with an original closing date of January 7, 2013, and it was archived on February 7, 2013. The full announcement was available through the NIH Grants Guide (linked in the listing), and support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster contact. Overall, PA-10-032 can be understood as an NCI effort to stimulate innovative epidemiologic studies that integrate epigenetic measurements into population research, with the aim of uncovering modifiable biological pathways and markers that help explain cancer risk and differences in risk across populations.
Frequently Asked Questions (FAQs): Epigenetic Approaches in Cancer Epidemiology (R21) - PA-10-032
What is the name of this grant opportunity?
The opportunity is titled "Epigenetic Approaches in Cancer Epidemiology (R21)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-10-032.
Which agency or institute offered this opportunity?
This opportunity was offered by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
What is the overall purpose of this FOA?
The FOA was designed to support exploratory, population-based research that connects epigenetic patterns to cancer risk across different groups of people. A key aim is to improve understanding of cancer etiology by identifying epigenetic markers that may help explain why cancer arises and why risk differs across populations.
What scientific approach was NCI trying to encourage?
The FOA encouraged moving beyond purely genetic explanations of cancer by examining epigenetic molecular features that can change over time and may be influenced by environment, behavior, aging, and other exposures.
What kinds of epigenetic profiles or markers were specifically mentioned?
The FOA specifically mentioned measuring and analyzing epigenetic profiles such as DNA methylation, histone modifications, and microRNA (miRNA) expression.
What type of studies were expected (population-based vs. lab-based)?
The FOA emphasized exploratory, population-based research, with an epidemiologic focus on linking epigenetic profiles to the likelihood of developing cancer across human populations or groups.
What grant mechanism did this opportunity use?
This opportunity used the NIH Exploratory/Developmental Research Grant mechanism (R21).
What is the intent of the R21 mechanism in this FOA?
In this FOA, the R21 mechanism was positioned for early-stage, proof-of-concept, or method-development work, including testing innovative ideas and generating preliminary data that could later support a larger, R01-scale project.
Was there a related R01 opportunity tied to the same scientific scope?
Yes. The FOA was described as a parallel companion to an R01 opportunity of the same scientific scope (PA-10-031), signaling interest in both smaller, higher-risk exploratory studies (R21) and larger, fully powered projects (R01).
What was the maximum award amount (award ceiling) listed?
The FOA listed an award ceiling of $200,000 (as provided in the source information).
Did the FOA guarantee a certain number of awards?
No. Awards were expected to depend on the availability of funds and the number of high-quality applications received, rather than a guaranteed fixed number of awards.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
What was the funding activity category and CFDA number?
The funding activity category was listed under Education/Health, and the CFDA number was 93.399 (Cancer Control).
What does the CFDA listing suggest about NCI program priorities?
It reflects placement within NCI's broader cancer control and population sciences priorities, consistent with the FOA's focus on cancer risk in populations and differences across groups.
Which types of organizations were eligible to apply?
Eligibility was broad and included public and private institutions of higher education, state governments, for-profit organizations (including those other than small businesses), small businesses, and nonprofit organizations with or without 501(c)(3) status (as long as they met the criteria described in the FOA).
Were federal agencies eligible?
Yes. The eligibility language explicitly included eligible federal agencies.
Were non-U.S. (foreign) organizations eligible?
Yes. The eligibility language explicitly included non-U.S. (foreign) entities.
Were regional organizations eligible?
Yes. The eligibility language explicitly included regional organizations.
Does the FOA appear to allow international collaborations or comparisons across populations?
Yes. By explicitly including non-U.S. entities and emphasizing population comparisons and unique cohorts, the opportunity indicates openness to a wide range of collaborative structures, including international work where appropriate.
When was this opportunity posted and created?
The opportunity was posted and created on November 24, 2009.
What was the original closing date?
The original closing date was January 7, 2013.
When was the opportunity archived?
The opportunity was archived on February 7, 2013.
Where was the full announcement made available?
The full announcement was available through the NIH Grants Guide (linked in the listing for the opportunity).
Who was listed as the contact for access or linking issues?
Support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster contact.
What is the "bigger picture" goal of funding these projects?
The bigger picture goal is to improve understanding of cancer etiology by identifying epigenetic markers and potentially modifiable biological pathways that help explain cancer risk and differences in risk across populations.
Browse more opportunities from the same category: Education Health
Next opportunity: BJA FY 2010 G20 Summit Security Assistance Reimbursement Grant Program
Previous opportunity: Epigenetic Approaches in Cancer Epidemiology (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 032
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 032) also looked into and applied for these:
| Funding Opportunity |
|---|
| Transdisciplinary Research in Energetics and Cancer (U54) Apply for RFA CA 10 006 Funding Number: RFA CA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01) Apply for PA 10 035 Funding Number: PA 10 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R01) Apply for PAR 10 038 Funding Number: PAR 10 038 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 10 040 Funding Number: PAR 10 040 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 10 039 Funding Number: PAR 10 039 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Critical Illness and Injury in Aging (R03) Apply for PA 10 043 Funding Number: PA 10 043 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R01) Apply for PA 10 042 Funding Number: PA 10 042 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R21) Apply for PA 10 044 Funding Number: PA 10 044 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Immunotherapy Trials Network (U01) Apply for RFA CA 10 007 Funding Number: RFA CA 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Integrity in Collaborative Research (R21) Apply for RFA RR 10 001 Funding Number: RFA RR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Coordination Center for Transdisciplinary Research in Energetics and Cancer (Limited Competition U01) Apply for RFA CA 10 501 Funding Number: RFA CA 10 501 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Support Opportunity for Addiction Research (SOAR) for New Investigators (R03) Apply for RFA DA 10 015 Funding Number: RFA DA 10 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Multifunctional Drug and Gene Delivery Systems (R01) Apply for PAR 10 048 Funding Number: PAR 10 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R01) Apply for RFA DA 10 006 Funding Number: RFA DA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R21) Apply for RFA DA 10 007 Funding Number: RFA DA 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Academic Career Award (Parent K07) Apply for PA 10 058 Funding Number: PA 10 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 10 068 Funding Number: PAR 10 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 10 012 Funding Number: RFA DA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) Apply for RFA CA 10 502 Funding Number: RFA CA 10 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanism for Time Sensitive Drug Abuse Research (R01) Apply for PAR 10 072 Funding Number: PAR 10 072 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 032", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.